Viral Hepatitis A (HAV) management

Viral Hepatitis A (HAV) management

Definition

Hepatitis A virus (HAV) infection is an acute viral disease of the liver caused by a non-enveloped RNA virus belonging to the Picornaviridae family, genus Hepatovirus. Transmission occurs primarily through the fecal–oral route via contaminated food, water, or close personal contact. HAV does not cause chronic hepatitis but may rarely result in fulminant hepatic failure.

Epidemiology

• Incubation period: 14–28 days (average 28 days).

• Common in areas with poor sanitation and limited access to clean water.

• Most frequently affects children and young adults.

• Adults generally experience more severe disease than children.

Clinical Presentation

Prodromal Phase

• Fever

• Malaise and fatigue

• Anorexia

• Nausea and vomiting

• Myalgia

• Headache

• Right upper quadrant abdominal discomfort

I

cteric Phase

• Dark urine (bilirubinuria)

• Pale or clay-colored stools

• Jaundice

• Pruritus

• Hepatomegaly

• Abdominal pain

Less Common Features

• Arthralgia

• Skin rash

• Cholestatic hepatitis

• Fulminant hepatic failure (rare)

Investigations

Specific Diagnostic Tests

• Anti-HAV IgM antibody: confirms acute infection.

• Anti-HAV IgG antibody: indicates previous infection or immunity.

• HAV RNA PCR: confirmatory test where available.

Baseline Assessment

• Full Blood Picture (FBP)

• Liver Function Tests (ALT, AST, ALP, GGT, bilirubin, albumin)

• Renal Function Tests (RFT)

• Coagulation profile (PT/INR)

• Blood glucose

• Screening for other viral hepatitis infections (HBV, HCV, HDV, HEV) when indicated

Non-Pharmacological Management

• Adequate oral or intravenous hydration.

• Maintain adequate nutritional intake.

• Avoid alcohol consumption.

• Avoid hepatotoxic medications and herbal preparations.

• Rest as clinically indicated.

• Educate on hand hygiene and sanitation measures to reduce transmission.

Pharmacological Management

There is no specific antiviral therapy for HAV infection.

Supportive Treatment

• A: Paracetamol (PO) 500 mg–1 g 6–8 hourly when required for fever or pain (maximum recommended daily dose and avoid excessive use in severe liver dysfunction).

• Antiemetics and intravenous fluids may be administered when clinically indicated.

Management of Severe Disease

Hospital Admission Indications

• Severe dehydration

• Persistent vomiting

• Coagulopathy (INR >1.5)

• Hepatic encephalopathy

• Hypoglycemia

• Acute liver failure

• Significant jaundice with clinical deterioration

Acute Liver Failure

• Admit to a high-dependency unit or intensive care unit.

• Monitor neurological status, coagulation profile, glucose, electrolytes, and renal function.

• Early consultation with a hepatologist or specialist physician.

Prevention

• Hepatitis A vaccination where available.

• Safe drinking water and proper sanitation.

• Hand washing after toilet use and before food preparation.

• Appropriate food hygiene practices.

• Post-exposure prophylaxis with HAV vaccine or immunoglobulin according to national guidelines.

Referral

Refer to a specialist physician or higher-level facility if:

• Acute liver failure is suspected.

• Severe cholestatic hepatitis develops.

• There is prolonged jaundice (>3 months).

• Diagnostic uncertainty exists.

• Significant comorbid liver disease is present.

NoteHAV infection is usually self-limiting and resolves completely within weeks to months. Chronic infection does not occur. Fulminant hepatic failure is uncommon but may be life-threatening and requires urgent specialist management.